Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells

Biochemical Pharmacology

Volumn 73, Issue 2, 2007, Pages 298-307

  Zisowsky, Jochen ^a   Koegel, Susanne ^a   Leyers, Stefan ^a   Devarakonda, Krishna ^a   Kassack, Matthias U ^a   Osmak, Maja ^b   Jaehde, Ulrich ^a  

^a UNIVERSITY OF BONN   (Germany)

^b RUDER BO KOVI INSTITUTE   (Croatia)

Author keywords

Accumulation; Cisplatin; Efflux; Resistance; Transport; Uptake

Indexed keywords

CARRIER PROTEIN; CISPLATIN; COPPER TRANSPORTER 1 PROTEIN; DNA; MENKES PROTEIN; PLATINUM; WILSON DISEASE PROTEIN;

ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; DNA REPAIR; DRUG SENSITIVITY; DRUG UPTAKE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; NUCLEOTIDE SEQUENCE; OVARY CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; TUMOR RESISTANCE;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CELL LINE, TUMOR; CISPLATIN; DNA; DNA PRIMERS; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION PROFILING; HUMANS;

EID: 33845222500     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.10.003     Document Type: Article

References (42)

1. Highley M.S., and Calvert A.H. Clinical experience with cisplatin and carboplatin. In: Kelland L.R., and Farrell N. (Eds). Platinum-based drugs in cancer therapy 7 (2000), Humana Press Inc., Totawa, NJ 171-194
2. Fink D., and Howell S.B. How does cisplatin kill cells?. In: Kelland L.R., and Farrell N. (Eds). Platinum-based drugs in cancer therapy 7 (2000), Humana Press Inc., Totawa, NJ 149-167
3. Fuertes M.A., Alonso C., and Perez J.M. Biochemical modulation of cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chem Rev 103 (2003) 645-662
4. Akiyama S., Chen Z.S., Sumizawa T., and Furukawa T. Resistance to cisplatin. Anticancer Drug Des 14 (1999) 143-151
5. Jordan P., and Carmo-Fonseca M. Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci 57 (2000) 1229-1235
6. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22 (2003) 7265-7279
7. Brozovic A., Fritz G., Christmann M., Zisowsky J., Jaehde U., Osmak M., et al. Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance. Int J Cancer 112 (2004) 974-985
8. Lin X., Okuda T., Holzer A., and Howell S.B. The copper transporter CTR1 regulates cisplatin uptake in saccharomyces cerevisiae. Mol Pharmacol 62 (2002) 1154-1159
9. Ishida S., Lee J., Thiele D.J., and Herskowitz I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 99 (2002) 14298-14302
10. Kruh G.D. Lustrous insights into cisplatin accumulation: copper transporters. Clin Cancer Res 9 (2003) 5807-5809
11. Safaei R., Holzer A.K., Katano K., Samimi G., and Howell S.B. The role of copper transporters in the development of resistance to Pt drugs. J Inorg Biochem 98 (2004) 1607-1613
12. Komatsu M., Sumizawa T., Mutoh M., Chen Z.S., Terada K., Furukawa T., et al. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res 60 (2000) 1312-1316
13. Holzer A.K., Samimi G., Katano K., Naerdemann W., Lin X., Safaei R., et al. The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol Pharmacol 66 (2004) 817-823
14. Katano K., Kondo A., Safaei R., Holzer A., Samimi G., Mishima M., et al. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res 62 (2002) 6559-6565
15. Osmak M., and Eljuga D. The characterization of two human cervical carcinoma HeLa sublines resistant to cisplatin. Res Exp Med 193 (1993) 389-396
16. Behrens B.C., Hamilton T.C., Masuda H., Grotzinger K.R., Whang-Peng J., Louie K.G., et al. Characterization of a cis-diamminedichloro-platinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 47 (1987) 414-418
17. Mueller H., Kassack M.U., and Wiese M. Comparison of the usefulness of the MTT, ATP, and calcein assays to predict the potency of cytotoxic agents in various human cancer cell lines. J Biomol Screen 9 (2004) 506-515
18. Kloft C., Eickhoff C., Schulze-Forster K., Maurer H.R., Schunack W., and Jaehde U. Development and application of a simple assay to quantify cellular adducts of platinum complexes with DNA. Pharm Res 16 (1999) 470-473
19. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3 7 (2002) RESEARCH0034
20. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25 (2001) 402-408
21. Mellish K.J., Kelland L.R., and Harrap K.R. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin. Br J Cancer 68 (1993) 240-250
22. Johnson S.W., Perez R.P., Godwin A.K., Yeung A.T., Handel L.M., Ozols R.F., et al. Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. Biochem Pharmacol 47 (1994) 689-697
23. Zhengdong L., and Duhong B. Experimental study on the mechanism of cisplatin resistance and its reversion in human ovarian cancer. Chin Med J 109 (1995) 353-355
24. Andrews P.A., Velury S., Mann S.C., and Howell S.B. cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res 48 (1988) 68-73
25. Loh S.Y., Mistry P., Kelland L.R., Abel G., and Harrap K.R. Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum(II) and (IV) ammine/amine complexes. Br J Cancer 66 (1992) 1109-1115
26. Parker R.J., Eastman A., Bostick-Bruton F., and Reed E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest 87 (1991) 772-777
27. De Pooter C.M., Van Oosterom A.T., Scalliet P.G., Maes R.A., and de Bruijn E.A. Correlation of the response to cisplatin of human ovarian cancer cell lines, originating from one tumor but with different sensitivity, with the recovery of DNA adducts. Biochem Pharmacol 51 (1996) 629-634
28. Yamada M., Tomida A., Yun J., Cai B., Yoshikawa H., Taketani Y., et al. Cellular sensitization to cisplatin and carboplatin with decreased removal of platinum-DNA adduct by glucose-regulated stress. Cancer Chemother Pharmacol 44 (1999) 59-64
29. Li Q., Yu J.J., Mu C., Yunmbam K., Slavsky D., Cross C.L., et al. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res 20 (2000) 645-652
30. Chao C.C. Decreased accumulation as a mechanism of resistance to cis- diamminedichloroplatinum(II) in cervix carcinoma HeLa cells: relation to DNA repair. Mol Pharmacol 45 (1994) 1137-1144
31. Johnson S.W., Laub P.B., Beesley J.S., Ozols R.F., and Hamilton T.C. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res 57 (1997) 850-856
32. Song I.S., Savaraj N., Siddik Z.H., Liu P., Wei Y., Wu C.J., et al. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther 3 (2004) 1543-1549
33. Beretta G.L., Gatti L., Tinelli S., Corna E., Colangelo D., Zunino F., et al. Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and -resistant cells. Biochem Pharmacol 68 (2004) 283-291
34. Safaei R., and Howell S.B. Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol 53 (2005) 13-23
35. Samimi G., Safaei R., Katano K., Holzer A.K., Rochdi M., Tomioka M., et al. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin Cancer Res 10 (2004) 4661-4669
36. Safaei R. Role of copper transporters in the uptake and efflux of platinum containing drugs. Cancer Lett 234 (2006) 34-39
37. Nakayama K., Miyazaki K., Kanzaki A., Fukumoto M., and Takebayashi Y. Expression and cisplatin sensitivity of copper-transporting P-type adenosine triphosphatase (ATP7B) in human solid carcinoma cell lines. Oncol Rep 8 (2001) 1285-1287
38. Katano K., Safaei R., Samimi G., Holzer A., Rochdi M., and Howell S.B. The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells. Mol Pharmacol 64 (2003) 466-473
39. Safaei R., Katano K., Larson B.J., Samini G., Holzer A.K., Naerdemann W., et al. Intracellular locatization and trafficking of fluorescein-labeled cisplatin in human ovarian carcinoma cells. Clin Cancer Res 11 (2005) 756-767
40. Nakayama K., Kanzaki A., Terada K., Mutoh M., Ogawa K., Sugiyama T., et al. Prognostic value of the Cu-transporting ATPase in ovarian carcinoma patients receiving cisplatin-based chemotherapy. Clin Cancer Res 10 (2004) 2804-2811
41. Higashimoto M., Kanzaki A., Shimakawa T., Konno S., Naritaka Y., Nitta Y., et al. Expression of copper-transporting P-type adenosine triphosphatase in human esophageal carcinoma. Int J Mol Med 11 (2003) 337-341
42. Kanzaki A., Nakayama K., Miyashita H., Shirata S., Nitta Y., Oubu M., et al. Mutation analysis of copper-transporting P-type adenosine triphosphatase (ATP7B) in human solid carcinomas. Anticancer Res 23 (2003) 1913-1915